Journals / Retina-Vitreus / 2016 / Cilt: 24 - Sayı: 3

Combined Intravitreal Triamcinolone-Bevacizumab Treatment in Refractory Diabetic Macular Edema

Dirençli Diyabetik Makula Ödeminde Kombine İntravitreal Triamsinolon-Bevacizumab Tedavisi

Pages
189–194
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Combined IVTA-IVB injection is safe and effective procedure diffuse DME refractory to anti-VEGF therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate the efficacy and safety of combined intravitreal triamcinolone acetonide (IVTA) and bevacizumab (IVB) injection diffuse diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor.
📊
Key Findings & Data:Materials and Methods: Twelve eyes of 12 diabetic patients (M/F:5/7, mean age 64.58±4.85 years) who were diagnosed as refractory DME to anti-VEGF injections were included in this study.
💡
Conclusion & Impact:Conclusions: Combined IVTA-IVB injection is safe and effective procedure diffuse DME refractory to anti-VEGF therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To investigate the efficacy and safety of combined intravitreal triamcinolone acetonide (IVTA) and bevacizumab (IVB) injection diffuse diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor. Materials and Methods: Twelve eyes of 12 diabetic patients (M/F:5/7, mean age 64.58±4.85 years) who were diagnosed as refractory DME to anti-VEGF injections were included in this study. Patients underwent combined injection of IVTA (preserver removed, 2 mg, 0.05 ml) and IVB (1.25 mg, 0.05 ml). The best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT) were measured at baseline, one, three, and six months (respectively) after combined IVB-IVTA injection. Results: The mean CMTs were 441.75±61.39 µ (mean±standart deviation), 392.83±68.24 µ, 325.67±66.67 µ, and 387.58±57.02 µrespectively. The mean BCVAs were 1.08±0.80 Log MAR, 0.82±0.71 Log Mar, 0.84±0.72 Log MAR, and 1.01±0.87 Log Mar respectively. The values of both BCVA and CMT at one, two, and three months were significantly improved from baseline ( p<0.05). After 6 months following combined injection 10 (%83.3) patients needed IV injection. Following the injection there was not any intra ocular reaction or inflammation. There were 4 (%33.3) patients with high IOP and their IOP's became normal with topical anti glaucomatous treatment. Conclusions: Combined IVTA-IVB injection is safe and effective procedure diffuse DME refractory to anti-VEGF therapy.

Özet

Amaç: Diffüz diyabetik makula ödemi (DMÖ)'nde intravitreal (İV) anti-'Vascular endothelial growth factor' (VEGF) tedaviye dirençli hastalarda kombine İV triamsinolon asetonid (İVTA) - bevacizumab (İVB) tedavisinin etkinlik ve güvenilirliğini araştırmak.Gereç ve Yöntem: Çalışmaya anti-VEGF tedaviye dirençli DMÖ tanısı olan 12 hastanın 12 gözü dahil edildi. Hastalara kombine İVTA (2 mg, 0.05 ml)-İVB (1.25 mg, 0.05 ml) enjeksiyonu uygulandı. Hastaların düzeltilmiş görme keskinlikleri (DGK), göz içi basıncı (GİB), santral makula kalınlığı (SMK), tedavi öncesi ve tedaviden 1ay, 3 ay, 6 ay sonra tekrarlandı. Bulgular: Hastaların kombine İVTA-İVB enjeksiyonu öncesi SMK'sı 441.75±61.39 µ (ortalama±standart sapma) olup kombine enjeksiyondan 1 ay sonraki SMK'sı 392.83±68.24 µ, 3 ay sonraki SMK'sı 325.67±66.67 µ ve 6 ay sonraki SMK'sı 387.58±57.02 µ olarak ölçüldü. Kombine enjeksiyon öncesine göre, enjeksiyondan 1 ay, 3 ay ve 6 ay sonraki kontrollerde SMK değerlerinde anlamlı azalma (p<0.05) görüldü. Kombine enjeksiyon öncesi DGK 1.08±0.80 LogMar olup kombine enjeksiyondan 1 ay sonraki DGK 0.82±0.71 LogMar, 3 ay sonraki DGK 0.84±0.72 LogMar, 6 ay sonraki DGK 1.01±0.87 LogMar olarak saptandı. Kombine enjeksiyon öncesine göre, enjeksiyondan 1 ay, 3 ay ve 6 ay sonraki kontrollerde DGK değerlerinde anlamlı artma görüldü. Kombine enjeksiyondan 6 ay sonraki kontrolde 10 (%83.3) hastaya tekrar İV enjeksiyon gerekti. Kombine enjeksiyon sonrası, hastaların hiçbirinde göz içi inflamatuar reaksiyonu veya enfeksiyonu gözlenmezken 4 (%33.3) hastada yüksek GİB saptandı. Bu hastaların GİB'i tedavi ile kontrol altına alındı. Sonuç: Diffüz DMÖ'de anti-VEGF tedaviye dirençli hastalarda, kombine İVTA-İVB tedavisi etkin ve güvenilirdir.

🔖

Cite This Article

BARDAK, H., BARDAK, Y., EKİM, M. M. (2016). Combined Intravitreal Triamcinolone-Bevacizumab Treatment in Refractory Diabetic Macular Edema. Retina-Vitreus, Cilt: 24 - Sayı: 3, 189–194. https://ajindex.com/articles/307994

References (12)

  1. Early treatment diabetic retinopathy study research group. Photocoagu- lation for diabetic macular edema. Early treatment diabetic retinopathy study report number 4. Int Ophthalmol Clin. 1987;27:265-72. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Dia. Res. 2007:95-103.
  2. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photoco- agulation. Arch Ophthalmology. 1992;110:1155-9.
  3. Van Meter ME, Kim ES. Bevacizumab current updates in treatment. Curr Opin Oncol. 2010;22:586-91.
  4. Kim J H, Kang S W, Ha H S, et al. Vitrectomy combined with intravit- real triamcinolone acetonide injection and macular laser photocoagu- lation for nontractional diabetic macular edema. Korean J Ophthalmol 2013;27:186-93.
  5. Weiwei Z, Hu R. Targeting carbonic anhydrase to treat diabetic retino- pathy: emerging evidences and encouraging results. Biochem Biophys Res Commun. 2009;18:368-71.
  6. Aiello LP, Davis MD. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-30.
  7. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated protein kinase C in vivo and supressed by an orally effective b-isoform-selective inhibitor. Dia- betes. 1997;46:1473-80.
  8. Tolentino MJ, Millet JW, Gragoudas ES, et al. Intravenous injections of vascular endothelial growth factor produce retinal ischemia and mic- roangiopathy in an adult primate. Ophthalmology. 1996;103:1820-28.
  9. Rich RM, Rosenfeld FJ, Puliofito CA, et al. Short-term safety and effi- cacy of intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
  10. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S. Comparison of int- ravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther. 2011;27:373-7.
  11. Ford JA, Elders A, Shyangdan D, et al. The relative clinical effective- ness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ 2012;345:5182. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and phar- macokinetics oftriamcinolone acetonide after a single intravitreal injec- tion. Ophtalmology. 2003;110:681-6.
  12. Biarnes M, Mones J,Villali JR, Arias L. As-needed treatment with ranibizumıab 0.5 mg in patients with neovascular age-related macular degeneration. Eur